Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TriPRIL CAR T Cells in Relapsed or Refractory Multiple Myeloma
NCT05020444Phase 1Active, not recruiting
- Start
- Oct 2021
- Primary completion
- Feb 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of APRIL CAR-T cells in multiple myeloma (MM) (2 arms). Primary endpoints: Adverse Events and Dose Limiting Toxicity. Started Oct 2021; status: active, not recruiting.
02
Drugs
APRIL CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05020444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05020444.